Furthermore, captopril modulates the immune response to tumors by increased infiltration of CD3+, attenuated tumor-infiltrating CD4+, and expression of checkpoint receptor PD-1 on the CD8+ cells and CD4 and CD8 double-negative T cells [389]. This evidence concerns the gene CD4 and neoplasm.